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Abstract
Backgroud: Pulmonary alveolar proteinosis is a rare disorder that is characterized by a large accumulation of
lipoproteinaceous material within the alveoli. This causes respiratory failure due to a restriction of gas exchange and
changes in the ventilation/perfusion ratio. Clinical symptoms are variable and depend on the severity of damage of
the lung parenchyma. Treatment method is whole-lung lavage, where the accumulated lipoproteinaceous material
is removed using large quantities of saline.
Case presentation: This case report describes a 45 year old patient with advanced pulmonary alveolar proteinosis.
Due to the presence of severe global respiratory insufficiency, this patient could not undergo the classic whole-
lung lavage using a double-lumen tube and selective lung ventilation. The whole-lung lavage was performed with
the support of veno-venous extracorporeal membrane oxygenation. A total of 27 l of warm saline was used.
Conclusion: According to the current published literature, whole-lung lavage with extra-corporeal membrane
oxygenation support is a very rare treatment method. Even when taking into account all of the risks associated
with whole-lung lavage and v-v extracorporeal membrane oxygenation support, we found that this technique is
very effective and, without a doubt, it saved the life of our patient.
Keywords: Pulmonary alveolar proteinosis (PAP), Whole-lung lavage (WLL), Extracorporeal membrane oxygenation
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Background
Pulmonary alveolar proteinosis (PAP) is a rare disorder
first described by Rosen and colleagues in 1958 [1].
This disease is characterized by an accumulation of
phospholipoproteinaceous material inside the alveoli
due to a disruption in surfactant homeostasis. The
prevalence of PAP is estimated to be around 4 cases
per 1 million. Males, smokers and persons between 30
and 50 years are most commonly affected. Symtoms in-
clude shortness of breath (dyspnea), cough and, in one
third of cases, nail clubbing. Opportunistic bacterial
and mycotic infections are common complications.
There is a variable interindividual progression of this
disease which can range from spontaneous recovery to
terminal cardiorespiratory failure. Diagnosis is based on
the results from bronchoalveolar lavage (BAL), hist-
ology and immunohistochemical tests, on the presence
of granulocyte-macrophage colony stimulating factor
(GM-CSF) antibodies and computer tomography (CT)
or high resolution computer tomography (HRCT) re-
sults which typically shows areas of patchy ground-
glass opacification and interlobular thickening, which
together produce the “crazy paving pattern” [2, 3].
PAP can occur as an acquired disease (primary or idio-
pathic PAP) and then is characterized by the production
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of GM-CSF antibodies, therefore is autoimmune in ori-
gin. Congenital forms of PAP are less commonly seen
and they are caused by a mutated gene responsible for
surfactant production or by a mutated receptor for GM-
CSF. These forms can be treated with medical therapy
(GM-CSF substitutes, biological treatment with mono-
clonal antibodies or plasmapheresis). Secondary forms of
PAP are associated with other illnesses, mainly hema-
tooncological diseases, exposure to anorganic materials
(eg. silicone), or from side-effect of medication such as
immunosuppresive drugs or amiodarone. Rarely, PAP
can be a part of the aquired immune deficiency syn-
drome (AIDS).
The treatment of aquired forms of PAP are mainly
bronchoalveolar lavage where the lungs are flushed out
with large quantities of saline. This can be performed on
individual lung segments, lobes or on the whole lung
with possibility for longer pauses between each lavage
treatment. The whole-lung lavage (WLL) has been de-
scribed as the most effective method of treatment [2, 3].
Case presentation
This is a case report of a 45-year old female with a history
of work exposure to a dusty environment. She was living
on a farm where the hens, rabbits and dogs were present
and also had a history of smoking 20 cigarettes a day for
19 years. The patient reported progressive worsening of
the shortness of breath on exertion for the last year. A
diagnosis of PAP was performed based on the HRCT and
BAL results. One-sided lung lavage was repeatedly per-
formed with the final procedure being complicated by
acute respiratory failure and the need for mechanical ven-
tilation. The therapeutic effect of the lavage treatments
was short-lived and was followed by progression of the
disease. Oxygen saturation on room air at rest (SpO2)
was measured as low as 80 %. The patient was therefore
dependent on a long-term home oxygen therapy. One year
following the diagnose of PAP, SpO2 at rest on room air
dropped to 72 %. The patient’s health status began to
deteriorate, withan insufficiency of the right heart devel-
oping and a Mycobacterium intracellular lung infection
was diagnosed and was subsequently repeatedly treated
with a combination of antibodies. High resolution com-
puted tomography results showed a severe ‘crazy paving’
pattern bilaterally. Arterial blood gas on home oxygen
therapy with O2 at 6L/min showed pO2 6.36 kPa and
pCO2 3.6 kPa. Due to rapid disease progression and the
presence of severe respiratory insufficiency, the patient
was indicated for the bilateral lung lavage and the proced-
ure was performed using veno-venous ECMO support.
The protocol recommended by the American College of
Chest Physicians from 2009 was followed during the per-
formance of this treatment [4].
Upon admission to the operating theatre, non-invasive
monitoring was commenced (electrocardiograph - ECG,
non-invasive blood pressure measurement – NIBP, pulse
oximetry). The initial values were as follows – sinus
rhythm 90/min, NIBP 160/90 mmHg, SpO2 ( on the
room air ) was 80 %. An 18 G peripheral venous cannula
was placed to the right cubital vein. Induction to general
anesthesia was commenced with remifentanil at 0.25 ug/
kg/min, 180 mg of propofol and 70 mg of rocuronium.
Tracheal intubation was performed with a 37 Ch
left-sided double-lumen tube without a carinal hook
(Robertshaw) and its position was confirmed with a
bronchoscope. A urinary catheter was inserted. The pa-
tient was ventilated using volume-controlled ventilation
(VCV) with a tidal volume of 480 mL during bilateral
lung ventilation, a respiratory rate of 10 breaths/min, an
inspiration:expiration ratio of 1:2, positive-end expira-
tory pressure (PEEP) of 5 cm H2O and the initial FiO2
was 1.0. Ventilation was adjusted based on the SpO2
and ETCO2 values until the introduction of the
v-v ECMO. Anesthesia was maintained intravenously
(TIVA) with propofol at a dosage of 0.7 mcg/Kg/min
and analgesia with remifentanil at a dosage of 0.16 mcg/
kg/min. Based on the recommendation of the Local
Hospital Drug Commitee, the procedure was performed
with antibiotic prophylaxis using 2g of cefotaxim 6
hourly.
After examination of both internal jugular veins and
femoral veins, a 8.5 Fr x 20 cm central venous catheter
was insered into the left internal jugular vein. Additionally,
a 8.5 Fr x 10 cm sheath was placed into the left subclavian
vein to allow for potential invasive monitoring using a pul-
monary catheter or in the instance that high-volume fluid
therapy would be necessary. Arterial cannulation was per-
formed on the left radial artery to ensure direct blood
pressure monitoring.
Selective ventilation of the right or left lung was not
possible due to the production of a right-left shunt
which would lead to the severe derangement of oxygen-
ation and highly increase the accumulation of CO2 in
the body.
Using transesophaegeal echocardiography (TEE), the
kinetics of the left and right heart were found to be nor-
mal without any valve pathology or pericardial separ-
ation. A bolus of heparin (5000 I.U.) was administered
prior to cannulation for the v-v ECMO. The infusion
cannula was placed in the right internal jugular vein
while the drainage cannula was placed in the right fem-
oral vein. The position of the both infusion cannulas was
confirmed using TEE. The flow through ECMO was set
at 4837 mL/min and was determined after calculating
the patient’s body surface area which was 1.79m2. After
reaching a flow of 4500 mL/min on the ECMO with a
FiO2 of 0.8, then the parametres of mechanical
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ventilation were adjusted accordingly (tidal volume - Vt
300-350 ml, respiratory frequency - RF 10 per minute,
PEEP 5 cmH2O, FiO2 0,4). Body core temperature was
measured in the esophagus. The activated clotting time
(ACT) was measured at precise intervals and heparin
boluses were given every 160-200 s.
After fixation of the ECMO cannulae, the patient was po-
sitioned on her right side. The position of the DLT was
checked with a bronchoscope. Prior to insertion, both cuffs
were tested under water for any leakage. The operating
table was placed in anti-Trendelenburg (“head up”) pos-
ition. Subsequently, the first 1000 mL of warmed (37 °C) sa-
line was introduced into the left lung, after which followed
a 4 min long manual physiotherapeutic massage of the
chest wall – using percussional postural massage and vibra-
tional techniques with the goal of freeing the maximal
amount of accumulated material. Afterwards, the fluid was
released with the help of gravity by placing the patient in
the Trendelenberg position (“head down”). This procedure
was repeated several times. At first, the collected fluid was
yellowish-white and cloudy with floccules that sedimented
and were collected. Progressively, the fluid became more
and more clear (Fig. 1).
After completing the lavage of the left lung, the patient
was positioned on her left side and the same procedure
was performed on the right lung. Over 225 min, the left
lung was rinsed with 12,000 mL of warm saline and
11,680 mL of the fluid was collected (320 mL were
absorbed) and over the course of 150 min, the right lung
was rinsed with 15,000 mL of warm saline and 14,530 mL
were collected (470 mL were absorbed). During the entire
procedure, several incidents of isolated hemodynamically
insignificant supraventricular and polytopic ventricular
ectopics were registered but did not require any interven-
tion. Normothermia was maintained for the duration
of the procedure. Electrolyte levels were monitored
throughout the procedure and the levels of potassium and
magnesium had to be corrected. Diuresis was supported
using furosemide at a dosage of 15 mg/h. In order to en-
sure proper perfusion, mean arterial pressure (MAP) was
maintained at 75 mmHg by continuous administration of
norepinephrine at a dosage of 0.10-0.15 ug/kg/min.
Oxygenation parameters during the procedure which
lasted 9 h are summarized at the Table 1.
The v-v ECMO flow was held at maximum values for
the entire duration of the procedure, in order to decrease
the amount of desaturated blood flow through the lung
undergoing lavage. The FiO2 values on the ECMO were
determined according to the patient paO2 and varied be-
tween 0.6 and 0.8 for the duration of the procedure. It is
clear from the initial oxygen values that without the use of
the v-v ECMO, the bilateral lung lavage would have
caused life threatening hypoxia. The patient’s life would
also have been endangered by significant hypercarbia lead-
ing to respiratory acidosis. The physiological value of
pCO2 was adjusted by changing of gas flow on the
ECMO.
After completion of the bilateral lung lavage, the pa-
tient was placed on her back and re-intubated with an
ordinary endotracheal tube size 7.5. A small amount of
remaining fluid was removed from the lungs bronchos-
copically. The sedated and hemodynamically stable pa-
tient was then moved to the intensive care unit with
continued support of the v-v ECMO. In the first few
hours post-op, there was a progressive worsening of oxy-
genation and a left-sided pneumothorax was diagnosed.
After the prompt insertion of a chest drain, this was
corrected. Due to an insufficient diuresis and risk of
hypervolemia, continuous renal replacement therapy
(CRRT) was initiated. Within three days, the CRRT and
v-v ECMO were discontinued and ventilatory weaning
was started On the 9th day, the patient was extubated, but
due to poor oxygenation and a hypoxemic index of 200,
she was soon placed on non-invasive ventilation. On the
11th day the patient was transferred from the ICU to the
Respiratory Care Department for further treatment.
Table 1 Oxygenation parameters during the procedure
Initial value FiO2 0.21 paO2 6.36 kPa SaO2 85 %,
SpO2 80 %
After induction FiO2 1.0 SpO2 93 %
v-v ECMO start FiO2 0.8 paO2 39.78 kPa SaO2 100 %
After 90 min of left
lung lavage, v-v ECMO
FiO2 0.6 paO2 16.16 kPa SaO2 98 %
225 min – end time
of left lung lavage,
v-v ECMO
FiO2 0.8 paO2 11.59 kPa SaO2 95,5 %
Next 150 min - end
time of right lung
lavage, v-v ECMO
FiO2 0.8 paO2 13,62 kPa SaO2 97,7 %
Fig. 1 The character of the first (on the left) and the last portions of
fluid used for the lung lavage
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Conclusion
Pulmonary alveolar proteinosis caused life-threatening
respiratory failure in our patient with SaO2 levels below
75 %. The only possibility for treatment was bilateral
bronchoalveolar lavage which would rinse the accumu-
lated lipoproteinaceous material out of the lungs using
warm saline. Abdelmalak et al. published [2] their
experience with high volume wash (up to 50 L in very
severe cases) without the need for ECMO and discussed
others´approach utilizing hyperbaric oxygen. Noirez
et al. presented [3] a 3-step strategy that was used in a
patient with PAP-associated refractory hypoxemia and
that combined venovenous extracorporeal membrane
oxygenation, double-lumen orotracheal intubation, and
bilateral multisegmental sequential lavage. In compliance
with current literature [2, 3] the oxygenation and
ventilation was assured by v-v ECMO and double-lumen
orotracheal intubation during the procedure. The oxy-
genation improved dramatically on v-v ECMO in our
patient. In the literature, a few similar cases have been
published [5, 6]. The first WLL was performed by
Ramirez in 1963 [7]. WLL can be performed with or
without ECMO [2, 3, 8]. The WLL procedure could be
accompanied by derangements of the acid–base and
electrolyte balance and hypervolemia [2, 8]. There is no
published information about quantity of absorbed chlor-
ide in current literature. In our case, 790 mL of saline
was absorbed by the lungs. The plasmatic level of the
chloride was checked repeatedly and remained within
the physiological range. Since severe generalized oedema
of soft tissues was observed together with a change in
diuresis, an undefined quantity of chloride is supposed
to have been absorbed into the third space. The type
of crystalloid to be used in this procedure has not
yet been standardized. Derangement of the electrolyte
homeostasis causing cardiac arrhythmias could be
avoided using Ringer‘s solution [5]. The WLL may
also be complicated by pneumotorax [9]. Standardized
protocols for WLL have not yet been established.
Other methods of treatment are GM-CSF substitutes
applied subcutaneously or inhalationally, biological
treatment with monoclonal antibodies, plasmapheresis,
hyperbaric oxygenoterapy and, in severe cases, even lung
transplantation [2, 3, 10]. In our case, we decided
for WLL with v-v ECMO support due to the severity
of the patient‘s clinical status and with full knowledge
of all associated risks. We found this technique to be
very effective and, without a doubt, it saved the life of our
patient.
Bilateral lung lavage with the support of VV-ECMO
is an effective, and often the only feasible, therapeutic
method in patients with pulmonary alveolar proteino-
sis. Quality multidisiplinary teamwork is extremely
important.
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